Showing 6781-6790 of 9552 results for "".
- Three Dermal Filler Patients Had Adverse Reactions to the Moderna COVID-19 Vaccinehttps://practicaldermatology.com/news/three-filler-patients-had-adverse-reactions-to-the-moderna-covid-19-vaccine/2460642/Three patients with dermal fillers have had adverse reactions to the Moderna COVID-19 vaccine, according to the Aesthetic Society. The FDA intends to note this in its prescribing information. There have been no reported cases in patients receiving the Pfizer COVID-19 vaccine.
- Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://practicaldermatology.com/news/ajinomoto-bio-pharma-services-and-revance-therapeutics-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2460641/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.
- Aerolase Introduces Skin of Color Forumhttps://practicaldermatology.com/news/aerolase-introduces-skin-of-color-forum/2460639/Aerolase Corp. is launching a Skin of Color Forum (SOCF). "This Forum is much needed and transformative. It's been rewarding to work alongside Aerolase to shape its leadership in advancing skin of color dermatology," sa
- FDA Defers Approval of Revance's Toxin Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspectionhttps://practicaldermatology.com/news/fda-defers-approval-of-revances-toxin-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection/2460628/The U.S. Food and Drug Administration (FDA) deferred a decision on the Biologics License Application (BLA) for Revance’s DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar lines. In a communication r
- Hoth Therapeutics Gets Greenlight to Start Phase 1b Trial of BioLexa for AD in Australiahttps://practicaldermatology.com/news/hoth-therapeutics-gets-greenlight-to-start-phase-1b-trial-of-biolexa-for-ad-in-australia/2460627/Hoth Therapeutics, Inc. received Human Research Ethics Committee clearance to commence the first cohort of the Phase 1b clinical trial of
- Olay Body Teams Up with Olympic Snowboarder Jamie Anderson to Reduce Winter Skin Drynesshttps://practicaldermatology.com/news/olay-body-teams-up-with-olympic-snowboarder-jamie-anderson-to-reduce-winter-skin-dryness/2460626/Olay Body is teaming up with professional snowboarder and 2X Olympic gold medalist, Jamie Anderson, to give women the tools they need to combat the snow and freezing temperatures that take a toll on skin. Olay Body also joined forces with Oro Valley, Ariz-based dermatologist Sheil
- Crown Aesthetics Scores Class IIa CE Certification for SkinPen Precision from British Standards Institutionhttps://practicaldermatology.com/news/crown-aesthetics-scores-class-iia-ce-certification-for-skinpen-precision/2460614/The British Standards Institution (BSI) granted a Class IIa CE Certification mark to Crown Aesthetics’ SkinPen Precision. The certification confirms SkinPen as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older and to improve the appe
- AAD Names Drs. Daval Bhanusali and Cory Maughan Patient Care Heroes for Treating Young Dog Bite Victimhttps://practicaldermatology.com/news/aad-names-drs-daval-bhanusali-and-cory-maughan-patient-care-heroes-for-treating-young-dog-bite-victim/2460611/Dhaval Bhanusali, MD, FAAD, and Cory Maughan, DO, FAAD, are American Academy of Dermatology (AAD) Patient Care Heroes for providing life-changing scar treatment to a young dog bite victim. Six-year-old Bridger Walker acted quickly and courageously when a dog tried to attack hi
- AAD Names Dr. Sacharitha Bowers a Patient Care Hero for Helping Address Disparities in Care Due to COVID-19https://practicaldermatology.com/news/aad-names-dr-sacharitha-bowers-a-patient-care-hero-for-helping-address-disparities-in-care-due-to-covid-19/2460610/Sacharitha Bowers, MD, FAAD, is an American Academy of Dermatology (AAD) Patient Care Hero for her role in addressing disparities in care related to COVID-19 in Springfield, Ill. Leveraging years of relationship-building with local organizations and community members, the Southern Illin
- More Positive Phase 3 Data for Pfizer's Abrocitinib in ADhttps://practicaldermatology.com/news/more-positive-phase-3-data-for-pfizers-abrocitinib-in-ad/2460607/Positive top-line results from the phase 3 JADE REGIMEN study offer additional data in support of Pfizer's investigational oral once-daily Janus kinase 1 (JAK1) inhibitor for atopic dermatitis (AD). The 52-week study looked at patients 12 and older wi